Watson Pharmaceuticals Incorporated (NYSE: WPI) was upgraded by analysts at Bank of America (NYSE: BAC) to a “buy” rating in a research report issued to clients and investors on Wednesday.

Separately, analysts at Collins Stewart cut their price target on shares of Watson Pharmaceuticals Incorporated from $75.00 to $60.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Analysts at Morgan Stanley (NYSE: MS) upgraded shares of Watson Pharmaceuticals Incorporated to an “overweight” rating in a research note to investors on Wednesday. They now have a $65.00 price target on the stock. Also, analysts at Cowen downgraded shares of Watson Pharmaceuticals Incorporated from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday.

Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. It operates in three segments: Global Generics, Global Brands and Distribution. It operates in international markets, including Western Europe, Canada, Australasia, Asia, South America and South Africa with its commercial market being the United States of America. As of December 31, 2010, it marketed approximately 160 generic pharmaceutical product families and approximately 30 brand pharmaceutical product families in the United States, and distributed approximately 8,500 stock-keeping units (SKUs) through its Distribution Division. In January 2010, the Company acquired 64% of Eden Biopharm Group Limited (Eden). In May 2011, it acquired Specifar Pharmaceuticals S.A.

Shares of Watson Pharmaceuticals Incorporated opened at 55.89 on Wednesday. Watson Pharmaceuticals Incorporated has a one year low of $53.46 and a one year high of $73.35. The stock’s 50-day moving average is $60.82 and its 200-day moving average is $65.24. The company has a market cap of $7.107 billion and a P/E ratio of 38.44.

Comments

Search RSS

All rights reserved."